Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Key Takeaways From Stauffer and Dan
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(37)
•••
Comment by PlaySafeon Aug 12, 2021 11:31am
181 Views
Post# 33691687

RE:RE:RE:RE:Key Takeaways From Stauffer and Dan

RE:RE:RE:RE:Key Takeaways From Stauffer and DanWhat is your confidence level that 75mg will be statistically signifigant to placebo over a two week period?  And the WOMAC scores of the 75mg trial will be compared to the WOMAC scores of Naproxen so even though the Phase 2 doesn't compare Antibe's drug to Naproxen you can't get away with comparing the WOMAC with previous NSAID studies.  Furthermore what is your confidence level of a 12 week phase 3 study and not seeing any anomolies in liver levels?  In other words do you think that the Antibe scientists know exactly the long term impact of their molecule?  If they did then they would have known to try lover doses during their Phase 2 trials and would have anticipated the AME issue.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities